Background
==========

Malignant liver tumors include primary and metastatic malignant tumors. In recent years, ^125^I-seed implantation has been found to show very good therapeutic effects on malignant liver tumors.[@b1-ott-10-3277] However, this treatment is always obscured by the costa and lung tissue, and displacement of the liver caused by breathing also makes treatment difficult. The use of 3-D printing template-assisted radioactive seed implantation could solve these problems and shorten operation time by optimizing radiation-dose distribution.[@b2-ott-10-3277],[@b3-ott-10-3277]

Materials and methods
=====================

Ethics statement
----------------

All patients in this study underwent treatment at the General Hospital of Shenyang Military Region (Shenyang, China). All clinical operations and investigations were approved by the ethical committee of the General Hospital of Shenyang Military Region, and all patients submitted signed consent forms.

General
-------

All patients who were chosen in our ward were treated from July 2014 to March 2016. Fifteen liver-tumor patients were treated with 3-D printing template-assisted radioactive seed implantation (group A), and 25 liver-tumor patients were treated with ^125^I-seed implantation without an auxiliary template as the control (group B) ([Table 1](#t1-ott-10-3277){ref-type="table"}). Inclusion criteria were a definite diagnosis of primary liver cancer, bile-duct carcinoma, or metastatic malignant liver tumor, good general condition (Karnofsky performance status \>60, liver function grade A or B), and having undergone chest radiography, electrocardiography, abdominal computed tomography (CT), and other laboratory examinations before treatment. A total of 24 patients from groups A and B had metastatic tumors, 21 patients accepted chemotherapy, and three patients accepted targeted therapy.

Instrumentation and equipment
-----------------------------

Materials used were a Philips MX 4000 dual-type CT scanner, 3-D printing template, 1122-type photosensitive resin, treatment-planning system (TPS) for brachytherapy (Prowess Panther Brachy version 5.0). Seed-implant devices used were puncture needles (18 and 21 G), a wheel disk-implant gun, and radioactive seeds (type 6711-99, particle activity 0.8 mCi, energy 27--35 keV, half-life 59.4 days). All particles were tested for activity before delivery, and notes were taken.

Therapeutic method
------------------

### Preoperative plan and 3-D template printing

3-D printing is based on data design files, the material deposited layer by layer to form a three-dimensional object.[@b4-ott-10-3277] The flexibility of 3-D printing allows investigators and manufacturers to create medical devices with a broad range of biological and physical properties. When paired with medical imaging, this flexibility may be leveraged to fabricate devices tailored to an individual patient's anatomy, such as a 3-D template. We can use the 3-D template to complete the example of implantation accurately, including outlining the target area, simulating the needle path, simulating the spatial position of the particle cloth, calculating the number of particles, and generating templates.[@b5-ott-10-3277] For group A, according to the nidus, a supine or prone position was chosen. Next, three hemispherical plastic tags of 0.7 cm were set near the operative area. CT scans were performed using 5 mm-thick lines, and included the whole liver and the position-mark point. The result was converted to the DICOM (digital imaging and communications in medicine) format and transferred to the TPS system. The target region was delineated, and the prescription dose was set at 12,000 cGy. Next, insertion of the pin was simulated, and then the pin and particle positions were adjusted so that the dose conformed to the following conditions: minimal periphery dose = prescription dose; D~90~ \> maximum permissible dose; V~100~ \>95%. After completing the preoperative plan, it was applied to the 3-D printing system to print the templates and order the particles. For group B, all procedures were performed as those in group A, except for application of the 3-D printing system and print templates ([Figure 1](#f1-ott-10-3277){ref-type="fig"}).

### Software algorithm

Stereolithography (STL) files were loaded in Materialise Magics version 9.51 software to select the regions of interest. Anatomical structures (bile ducts, hepatic arteries, hepatic veins, and portal veins) were digitally segmented with MeVis-supplied (MeVis Medical Solutions AG, Bremen, Germany) digital files from the optimal visualization phases of contrast-enhanced CT and magnetic resonance imaging (MRI). Subsequently, the geometry of each structure was exported to a mesh-type (STL) file to create a 3-D geometry of that structure. Digital preparation of the STL files was accomplished with the Magics software.

Therapeutic process
-------------------

The template should be placed according to the positioning mark, and a 21 G puncture needle can be used to administer local anesthesia. At this time, the patient should not breathe, an 18 G puncture needle should be used to insert the needle, and then the position should be checked by CT. If the needle is confirmed to be correctly positioned, then another two places are chosen to insert the needles in a similar way. If this did not conform to the plan, the patient should be instructed to breathe, and the puncture can be repeated until the position of the needle conforms to the plan. With three needles fixed to the template and liver, 18 G needles can be inserted according to the template, guided under local anesthesia, and the positions should be rechecked by CT to ensure that all of the needles are placed correctly and that the seeds were placed according to the plan. The needle can then be retreated gently. If bleeding occurs, the patient's own hemocoagulase can be used to stop the bleeding. The entire therapy should be performed with electrocardiography monitoring, and rescue supplies should be prepared.

### Postoperative validation

CT was performed immediately after seed implantation, using all conditions as described. The result was converted to the DICOM format and transferred to the TPS system to be verified postoperatively. The receiver postoperative isodose curve, dose-volume histogram, and other parameters were evaluated ([Figure 2](#f2-ott-10-3277){ref-type="fig"}).

### Therapeutic evaluation and side effects observed and followed

All patients who accepted radioactive particle-implantation treatment were rechecked with CT or MRI after 1, 2, and 3 months. Nidus size was compared with that determined 2 months previously. The largest diameter of the tumor was measured, all nidus diameters were added, and then statistical analysis was performed. According to Response Evaluation Criteria in Solid Tumors 1.1, complete response (CR), partial response (PR), no change, and progressive disease were determined: $$\text{Response~rate} = \frac{\text{CR} + \text{PR}}{\text{Number~of~cases~of~follow-up}} \times 100\%.$$

Statistical methods
-------------------

Two groups of data were subjected to *χ*^2^ test, and measurement data were evaluated using *t*-tests and SPSS 19.0. *P*\<0.05 indicated statistical significance.

Results
=======

All patients in the two groups underwent radioactive particle-implantation treatment successfully ([Table 2](#t2-ott-10-3277){ref-type="table"}). Compared with group B, duration in group A was shorter, D~100~ and V~100~ were closer to the prescribed dose, V~150~ was smaller, and the dose distribution was more precise. Differences between the groups showed statistical significance. Efficacy comparison of the two groups is shown in [Table 3](#t3-ott-10-3277){ref-type="table"}, and differences between the groups showed no statistical significance. Complication comparison is shown in [Tables 4](#t4-ott-10-3277){ref-type="table"} and [5](#t5-ott-10-3277){ref-type="table"}.

Discussion
==========

Radioactive particle implantation has the characteristics of a small trauma operation, providing a high treatment dose in the tumor target area and only minor injury to normal tissue. In recent years, radioactive particle-implantation treatment has increasingly been used in solid malignant tumors and other treatments and achieved good therapeutic effect.[@b6-ott-10-3277],[@b7-ott-10-3277] Peng et al[@b8-ott-10-3277] reported transarterial chemoembolization (TACE) combined with ^125^I particles in the treatment of 32 cases of primary liver cancer and TACE alone in a group of 43 patients. Results of the control group and combined-treatment group were 60.5% (26 of 43) and 84.4% (27 of 32), respectively, and the difference was significant (*P*\<0.05). Median survival times were 19.5 and 22.9 months, respectively, and the difference was significant (*P*\<0.05). Therefore, TACE combined with ^125^I particles in the treatment of primary liver cancer is safe and effective. Zhang et al reported CT-guided ^125^I seed implantation in the treatment of liver cancer recurrence after liver transplantation and extrahepatic metastases. The matched peripheral dose was 100--150 Gy, and the total effectiveness rate was 82.2%. The main complications were pneumothorax, a small amount of bleeding, a small shift in white blood-cell count, and a slight reduction in the number of white blood cells. For treatment of liver cancer recurrence and metastasis of liver tumors after liver transplantation, ^125^I seeds implanted under CT guidance are effective, less invasive, and cause fewer complications.[@b9-ott-10-3277] Because the liver puncture is often blocked by the ribs, respiratory movement, tumor-infiltration range, and irregular shape, as well as other factors, it is often difficult to implement preoperative planning accurately, resulting in poor dose distribution at the tumor lesion, which affects tumor treatment, the ability to control the quality of the treatment technology, and universal standardization of the treatment plan.

Computer-aided design of the 3-D printing template can accurately map the preplanned information of the needle track to the individual template to achieve precise implementation of the treatment plan and optimize dose distribution within the target area. The use of 3-D printing of individual templates also allows the treatment process to be simple and effective, allows the continuous treatment of multiple lesions, shortens operation time, and improves patient tolerance. Zhang et al reported CT guidance combined with the use of the 3D printing template to guide the implantation of radioactive particles in the treatment of recurrent retroperitoneal tumor success.[@b9-ott-10-3277] Huang et al[@b10-ott-10-3277] reported the use of 3-D printing template CT-guided ^125^I implantation in 31 patients with head and neck cancer recurrence and locally advanced cancer patients, and D~90~, V~100~, and V~150~ achieved the treatment requirements, revealing that individual 3-D printing templates can make radioactive particle-implantation treatment simpler and more accurate.

Liver puncture is affected by breathing; therefore, our approach is to ask patients with shallow breathing in the inspiratory phase to hold their breath for 2 seconds, and a scan is used to position the needle; not only can patients maintain a sufficiently long breath hold to exclude gas time but this technique can also reduce pain caused by inspiratory changes in patients with aspiration that would impact the puncture. Scanning during the puncture (after deep inspiration) is performed to verify this method of holding the breath; the result is more accurate and easy to confirm. If the needle is found to be deviated from the predetermined position during scanning, it can be retracted to the subcutaneous adjustment direction and then used for repuncture until the predetermined position is reached. Usually, the first needle is the most difficult to achieve puncture, and subsequent needle puncture is relatively easy. The location of tumor foci is relatively fixed; therefore, puncture of the needle path through sensitive areas, such as the gallbladder, portal vein, hepatic vein, and near the top of the diaphragm, can be avoided by using the scan to verify the needle is positioned in the desired location. The remaining puncture needle can be positioned using the preset template position.

Lesions around the top of the phrenic nerve are always sheltered from the diaphragm and lung tissue and also affected by respiratory movement. Because of the requirement of location, we needed to puncture many times, possibly leading to bleeding, pneumothorax, hemopneumothorax, and other side effects. A 3-D printing template has accurate space-orientation function.[@b11-ott-10-3277] Fifteen liver-tumor patients with 47 total lesions were treated with 3-D printing template-assisted radioactive seed implantation, and operation time was significantly shortened compared with the control group.

After particle implantation, verification of quality confirmed that D~100~, V~100~, and V~150~ had statistically significant differences between the groups. The template-assisted group's matched peripheral dose was improved, target-zone high-dose area was smaller, and dose distribution conformed more closely to preoperative planning. The template-assisted group had a higher effective rate than the control group, but with no statistical significance, which may have been due to the low number of cases in this study.

Regarding complications, one patient in the control group exhibited hemothorax. After hemostasis, fluid infusion, blood transfusion, and other symptomatic treatment, the bleeding was stopped. Two months later, the pleural fluid was completely absorbed. Patients with lesions located under the diaphragm underwent cryoablation. The puncture position was close to the original puncture point. Vascular elasticity was decreased, implying that any hemorrhage might have been due to perivascular tissue organization. Another two patients with lesions located under the diaphragm in the control group developed pneumothorax caused by coplanar puncture damage to pleura and lung tissue. Prompt application of the 3-D printing template assisted by noncoplanar puncture can reduce diaphragmatic-targeted biopsy complications.

The results of this study suggest that 3-D printing template-assisted ^125^I-seed implantation in the treatment of malignant liver tumors can reduce operation time, optimize radiation-dose distribution, and show satisfactory results. However, because of the retrospective nature of the study, which included a small number of patients, some bias effects exist, such as patient compliance. In future, large-scale prospective randomized studies are needed to validate the clinical value of 3-D printing template-assisted ^125^I-seed implantation in treatment.
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![Use of TPS to design the needle-insert and seed-arrangement plane according to CT result for printing 3-D templates.\
**Abbreviations:** TPS, treatment-planning system; CT, computed tomography.](ott-10-3277Fig1){#f1-ott-10-3277}
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###### 

General characteristics of the patients

  Characteristic                        Group A        Group B        *P*-value
  ------------------------------------- -------------- -------------- -----------
  **Sex, n (%)**                                                      0.869
  Male                                  8/15 (53.3)    14/25 (56)     
  Female                                7/15 (46.7)    11/25 (44)     
  **Age, years**                                                      0.334
  Median (range)                        61 (42--78)    57 (37--82)    
  **KPS, n (%)**                                                      0.622
  70                                    9 (60)         13 (52)        
  60                                    6 (40)         12 (48)        
  **Diagnosis, n (%)**                                                0.95
  Primary hepatocellular carcinoma      6/15 (40)      10/25 (40)     
  Cholangiocarcinoma                    2/15 (13.3)    5/25 (20)      
  Liver metastasis from rectal cancer   4/15 (26.7)    6/25 (24)      
  Liver metastasis from other cancers   3/15 (20)      4/25 (20)      
  **Number of lesions, n (%)**                                        0.908
  One                                   3/15 (20)      5/25 (20)      
  Two                                   4/15 (26.7)    9/25 (36)      
  Three                                 3/15 (20)      5/25 (20)      
  More                                  5/15 (33.3)    6/25 (24)      
  **Total lesions, n**                  47             66             
  **Lesion size, n (%)**                                              0.139
  ≤3 cm                                 14/47 (29.8)   27/66 (40.9)   
  3--8 cm                               29/47 (61.7)   34/66 (51.5)   
  \>8 cm                                4/47 (8.5)     5/66 (7.6)     
  **Location of lesions, n (%)**                                      0.006
  Right lobe of liver                   19/47 (40.4)   20/66 (30.3)   
  Left lobe of liver                    15/47 (31.9)   31/66 (46.9)   
  Caudate lobe of liver                 11/47 (23.4)   13/66 (19.7)   
  Quadrate lobe of liver                2/47 (4.3)     23/66 (3.1)    

**Abbreviation:** KPS, Karnofsky performance.

###### 

Operation data

                             Group A        Group B        *t*    *P*-value
  -------------------------- -------------- -------------- ------ --------------------------------------------------
  Operation time (minutes)   42.5±19.3      67.6±37.2      2.4    0.01[\*](#tfn2-ott-10-3277){ref-type="table-fn"}
  Number of operations       1.3±0.6        1.5±0.8        0.8    0.2
  Hospital stay (days)       7.1±5.2        9.7±6.8        1.27   0.11
  D~90~ (cGy)                12,426±2,324   10,985±3,656   1.37   0.18
  D~100~ (cGy)               10,307±2,489   7,764±2,582    3.06   0.04[\*](#tfn2-ott-10-3277){ref-type="table-fn"}
  V~100~ (%)                 95.4±6.5       89.6±8.4       2.29   0.01[\*](#tfn2-ott-10-3277){ref-type="table-fn"}
  V~150~ (%)                 62.1±14.2      73.6±15.6      2.33   0.01[\*](#tfn2-ott-10-3277){ref-type="table-fn"}

**Note:**

Statistically significant.

###### 

Response (rate) results, n (%)

                                                         Group A        Group B
  ------------------------------------------------------ -------------- ------------
  CR                                                     3 (20)         3 (12)
  PR                                                     10 (66.7)      18 (72)
  NC                                                     1 (6.7)        1 (4)
  SD                                                     1 (6.7)        3 (12)
  Responses[a](#tfn3-ott-10-3277){ref-type="table-fn"}   13/15 (86.7)   21/25 (84)

**Note:**

*χ*^2^=0.05, *P*=0.819 (not significant).

**Abbreviations:** CR, complete response; PR, partial response; NC, no change; SD, stable disease.

###### 

Complications of permanent ^125^I implantation

  -------------------------------------------------------------
                     Group A\   Group B\   *χ*^2^   *P*-value
                     n (%)      n (%)               
  ------------------ ---------- ---------- -------- -----------
  Pain               7 (46.7)   11 (44)    0.027    0.87

  Fever              5 (33.3)   6 (24)     0.409    0.52

  Massive bleeding   0          1 (4)      --       --

  Pneumothorax       0          2 (8)      --       --

  Seeds migration    2 (13.3)   1 (4)      1.177    0.28
  -------------------------------------------------------------

###### 

Patients suffering from varying degrees of complication

  ------------------------------------------------------
            Group A,\   Group B,\   *χ*^2^   *P*-value
            n (%)       n (%)                
  --------- ----------- ----------- -------- -----------
  Grade 1   7 (46.7)    16 (36)     2.67     0.1

  Grade 2   4 (28.5)    3 (12)      12       0.052

  Grade 3   0 (0)       0 (0)       --       --

  Grade 4   0 (0)       0 (0)       --       --

  Grade 5   0 (0)       0 (0)       --       --
  ------------------------------------------------------

**Note:** Complications evaluated with CTCAE grading scale (version 4.03).

**Abbreviation:** CTCAE, Common Terminology Criteria for Adverse Events.
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